Real-world outcomes in patients with AML and MDS treated with Azacitidine

被引：0
|
作者：
Prusak, E. [1 ]
Lawes, M. [2 ]
Collins, A. [2 ]
机构：
[1] Norfolk & Norwich Univ Hosp, Norwich, Norfolk, England
[2] Norfolk & Norwich Univ Hosp, Haematol, Norwich, Norfolk, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 181卷
关键词：
AML; Azacitidine; mds;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH18-PO-0
引用
收藏
页码：42 / 42
页数：1
相关论文
共 50 条
  • [41] Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group
    Katharina Götze
    Uwe Platzbecker
    Aristoteles Giagounidis
    Detlef Haase
    Michael Lübbert
    Carlo Aul
    Arnold Ganser
    Ulrich Germing
    Wolf-Karsten Hofmann
    Annals of Hematology, 2010, 89 : 841 - 850
  • [42] Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group
    Goetze, Katharina
    Platzbecker, Uwe
    Giagounidis, Aristoteles
    Haase, Detlef
    Luebbert, Michael
    Aul, Carlo
    Ganser, Arnold
    Germing, Ulrich
    Hofmann, Wolf-Karsten
    ANNALS OF HEMATOLOGY, 2010, 89 (09) : 841 - 850
  • [43] Comparison of clinical outcomes of several risk stratification tools in newly diagnosed AML patients: A real-world evidence in our current therapeutic era
    Iat, Alexandre
    Loschi, Michael
    Benachour, Sami
    Calleja, Anne
    Chiche, Edmond
    Sudaka, Isabelle
    Aquaronne, Daniele
    Ferrero, Corinne
    Fenwarth, Laurene
    Marceau, Alice
    Fournier, Elise
    Dadone-Montaudie, Berengere
    Cluzeau, Thomas
    CANCER MEDICINE, 2024, 13 (06):
  • [44] Real-world outcomes and prognostic factors among patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation
    Wang, Qingya
    Liang, Zeyin
    Ren, Hanyun
    Dong, Yujun
    Yin, Yue
    Wang, Qingyun
    Liu, Wei
    Wang, Bingjie
    Han, Na
    Li, Yangliu
    Li, Yuan
    ANNALS OF HEMATOLOGY, 2023, 102 (11) : 3061 - 3074
  • [45] Phase 2 Study of Pevonedistat plus Azacitidine versus Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (LB-AML) (NCT02610777): Subset Analysis in Higher-Risk MDS
    Watts, Justin
    Ades, Lionel
    Radinoff, Atanas
    Arnan Sangerman, Montserrat
    Cerrano, Marco
    Font Lopez, Patricia
    Zeidner, Joshua
    Campelo, Maria Diez
    Graux, Carlos
    Liesveld, Jane
    Selleslag, Dominik
    Tzvetkov, Nikolay
    Fram, Robert J.
    Zhao, Dan
    Bell, Jill
    Friedlander, Sharon
    Faller, Douglas V.
    Sekeres, Mikkael A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S323 - S324
  • [46] Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients
    Donnette, Melanie
    Hamimed, Mourad
    Ciccolini, Joseph
    Sicard, Guillaume
    Correard, Florian
    Farnault, Laure
    Ouafik, L'Houcine
    Venton, Geoffroy
    Fanciullino, Raphaelle
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 203 (04) : 625 - 636
  • [47] Multi-Gene Molecular MRD by Digital PCR is Prognostic of Outcomes in AML Treated With Venetoclax/Azacitidine
    Winters, Amanda
    Minhajuddin, Mohd
    Stevens, Brett
    Major, Ajay
    Miltgen, Nicholas
    Yuan, Ji
    Treece, Amy
    Gutman, John
    Jordan, Craig
    Pollyea, Daniel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S278 - S279
  • [48] The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda"
    Molteni, Alfredo
    Riva, Marta
    Borin, Lorenza
    Bernardi, Massimo
    Pelizzari, Anna Maria
    Freyrie, Alessandra
    Della Porta, Matteo
    Nichelatti, Michele
    Ravano, Emanuele
    Quaresmini, Giulia
    Mariotti, Jacopo
    Caramazza, Domenica
    Ubezio, Marta
    Guarco, Simona
    Gigli, Federica
    Greco, Rosa
    Cairoli, Roberto
    Morra, Enrica
    LEUKEMIA RESEARCH, 2016, 42 : 21 - 27
  • [49] Nature of Clinical Response and Depth of Molecular Response in Patients With TP53-Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Treated With Magrolimab With Azacitidine
    Johnson, Lisa
    Zhang, Yajia
    Li, Biao
    Aviles, Lisa
    Daver, Naval G.
    Vyas, Paresh
    Sallman, David A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S362 - S362
  • [50] Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
    Matthews, Andrew H.
    Perl, Alexander E.
    Luger, Selina M.
    Loren, Alison W.
    Gill, Saar I.
    Porter, David L.
    Babushok, Daria V.
    Maillard, Ivan P.
    Carroll, Martin P.
    Frey, Noelle V.
    Hexner, Elizabeth O.
    Martin, Mary Ellen
    McCurdy, Shannon R.
    Stadtmauer, Edward A.
    Paralkar, Vikram R.
    Bruno, Ximena Jordan
    Hwang, Wei -Ting
    Margolis, David
    Pratz, Keith W.
    BLOOD ADVANCES, 2022, 6 (13) : 3997 - 4005
12345